FINWIRES · TerminalLIVE
FINWIRES

多倫多證券交易所午盤上漲455點,醫療保健和原物料板塊表現最佳。

By

-- 多倫多證券交易所午盤上漲455點,部分收復了先前連續五個交易日下跌630點的部分失地。 表現最佳的板塊是醫療保健(+3.6%)和原料(+2.3%)。博士倫健康(BHC.TO)週三收盤後公佈的利潤超出預期,股價上漲近10%,至8.41加元。 加拿大統計局今日公佈的數據顯示,2月加拿大實際GDP成長0.2%,而3月和第一季的初步數據顯示,加拿大經濟「遠未達到全面復甦狀態」。 加拿大帝國商業銀行 (CIBC) 的安德魯·格蘭瑟姆 (Andrew Grantham) 表示:「儘管第一季的成長似乎接近加拿大央行貨幣政策報告 (MPR)的預測,但3月份再次出現的停滯令人擔憂,因為這關係到春季的增長勢頭。 消費者支出似乎再次放緩,考慮到汽油價格上漲帶來的壓力以及勞動力市場依然疲軟,這種情況是可以理解的。 加拿大國家銀行則表示,最新數據顯示,儘管面臨許多不利因素,加拿大經濟在第一季仍維持了穩健成長。儘管3月經濟出現預期中的停滯,但按行業劃分的GDP顯示,今年第一季按年率計算成長了1.7%。該行指出,19個行業中至少有12個行業在第一季實現了成長。 「在正常情況下,這樣的成長會被認為是可觀的,但同時,人口卻在萎縮,這抑制了經濟的潛在GDP成長。因此,人均GDP有望迎來15個季度以來的最強勁增長(年化增長率2.1%)。對於一個供應過剩且失業率高於充分就業水準的經濟體來說,這無疑是個好消息。」加拿大國家銀行表示好消息。 「然而,」該行補充道,「過去的表現並不能保證未來成長的持續。由於關稅的不確定性以及當前的全球地緣政治局勢,加拿大經濟仍然十分脆弱。雖然大宗商品價格上漲可能對某些行業有利,但潛在的利好將被消費者面臨的負面影響所抵消,因為消費者正面臨著通脹效應,美國全國主要飆升的困境。 在股市方面,龐巴迪(BBD-B.TO)股價上漲 17%,至 279.86 美元,此前該公司公佈的第一季度盈利超出預期。

Related Articles

Sectors

Sector Update: Financial

Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.

$AVB$EQR
Australia

Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid

Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%

$AAPL$META
Australia

Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation

Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%

$AXSM